Tetsu Maruyama

Tetsu Maruyama is the Chief Scientific Officer for the Dementia Discovery Fund (DDF), an innovative venture fund managed by SV Health Investors and dedicated to creating novel and innovative treatments for dementia. Tetsu’s background is in neuroscience, having received his PhD from Stanford University and conducting post-doctoral research at Yale University. Tetsu has worked in academia in the US and the UK, and at major pharmaceutical companies such as Merck Sharpe and Dohme, GSK (where he was the Director of the GSK Centre for Cognitive and Neurodegenerative Disorders in Singapore) and Takeda Pharmaceutical Company in Japan. At Takeda, Tetsu held positions as Head of CNS Research and later Head of Global Drug Discovery. Tetsu is on the board of a number of biotech companies and public-private partnerships including the Structural Genomics Consortium, and is a member of the World Dementia Council.